Castration-resistant Prostate Cancer
📧 Sign up to get email alerts when something new happens for Castration-resistant Prostate Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC [Phase 1]
An ongoing Phase 1 (Phase Ib) clinical trial is evaluating REGN5678 in combination with cemiplimab for metastatic castration-resistant prost…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer [Phase 1]
Phase 1 study evaluating nivolumab in combination with Radium-223 in men with metastatic castration-resistant prostate cancer; the trial is …
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer [Phase 2]
A Phase 2 clinical trial of SYNC-T Therapy SV-102 for metastatic castration-resistant prostate cancer is currently recruiting. The sponsor i…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Study of INKmune in Patients With mCRPC (CaRe Prostate) [Phase 1, Phase 2]
The update notes the completion of a Phase 1/2 study of INKmune in metastatic castration-resistant prostate cancer (CaRe Prostate) sponsored…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer [Phase 1, Phase 2]
Regeneron is conducting a Phase 1/2 clinical trial to evaluate REGN4336 alone and in combination with cemiplimab or REGN5678 for adults with…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer [Phase 2]
Phase 2 clinical trial evaluating enzalutamide with or without radium-223 dichloride in metastatic castration-resistant prostate cancer is c…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation [Phase 2]
A Phase 2 clinical trial of checkpoint inhibitors in men with progressive metastatic castration-resistant prostate cancer characterized by m…
-
CLINICAL_TRIALS trial_result · 2026-02-25Clinical Trial Update: A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer
Pfizer-sponsored clinical trial evaluating enzalutamide versus abiraterone in metastatic castration-resistant prostate cancer has completed …
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC [Phase 3]
Novartis is running a Phase 3 trial comparing AAA817 combined with an androgen receptor pathway inhibitor (ARPI) versus standard of care in …
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer [Phase 1]
A Phase 1 trial update for DS9051b in advanced or metastatic adrenocortical carcinoma and metastatic castration-resistant prostate cancer, c…
-
CLINICAL_TRIALS other · 2026-02-24Clinical Trial Update: Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer [Phase 4]
Phase 4 clinical trial update on cognitive effects of androgen receptor-directed therapies in advanced prostate cancer; the study is current…
-
CLINICAL_TRIALS trial_result · 2026-02-23Clinical Trial Update: Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors [Phase 1]
Phase 1 study evaluating the safety and activity of BPX-601, a PSCA-targeted CAR-T cell therapy, in selected advanced solid tumors including…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer [Phase 1]
Phase 1 clinical trial update for CART-PSMA-TGFβRDN cells targeting prostate cancer; the study is active but not recruiting.
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors [Phase 1, Phase 2]
This is a Phase 1/2 clinical trial evaluating GVV858 as a single agent or in combination with endocrine therapy for hormone receptor-positiv…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: COMPASS Study for Metastatic Castration-resistant Prostate Cancer
The COMPASS trial at Duke University is currently recruiting for metastatic castration-resistant prostate cancer.
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy [Phase 1]
Phase 1 study of ITC-6146RO in patients with advanced or metastatic cancers after standard therapy; the trial is not yet recruiting.
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer
An observational study evaluating lutetium-177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer is currently recrui…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study). [Phase 1, Phase 2]
This entry describes a Phase Ib/IIa dose-escalation and expansion trial of the radiopharmaceutical [212Pb]Pb-ADVC001 for metastatic prostate…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the safety of different doses of olaparib given with radium-223 in men with advanced prostate cancer w…
-
EMA approval · 2026-02-18EMA Authorised: Pluvicto (lutetium (177Lu) vipivotide tetraxetan) — Novartis Europharm Limited
The EMA authorised Pluvicto (lutetium-177 vipivotide tetraxetan) for metastatic castration-resistant prostate cancer. It is a PSMA-targeted …
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer [Phase 1]
A Phase 1 clinical trial to evaluate the safety and drug levels of ASP5541 in Chinese participants with prostate cancer is currently recruit…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
Trial exploring whether DNA repair pathway alterations affect Radium-223 efficacy in bone-metastatic castration-resistant prostate cancer; c…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/Phase 2 study of 225Ac-J591 for progressive metastatic castration-resistant prostate cancer, …
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial is investigating STEAP1-targeted CAR-T cell therapy in combination with enzalutamide for metastatic castration-re…
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study of pembrolizumab (MK-3475) combination therapies for metastatic castration-resistant …